Evaluation of Biomarkers in Myoma Patients: A Prospective Study Investigating the Role of LDH, CA 125, and IGF-1 after Uterus-Preserving Surgical Therapy

Objective: Myomas are one of the most common tumors of the lower abdomen in women. At present, sonography and clinical examination are the prevalent diagnostic standards for these tumors, and no biomarkers have been established yet. The primary aim of this study was to determine if the surgical removal of myomas leads to a drop of lactate dehydrogenase (LDH), CA 125, and/or insulin-like growth factor (IGF-1) and therefore if these parameters are suitable as potential biomarkers for the presence or recurrence of a myoma. Study Design: The blood levels of LDH, CA 125, and IGF-1 were determined in 83 patients (age 18–50) with a verified diagnosis of myomas and surgical therapy at 3 different timepoints: preoperative (T0), 2 days postoperative (T1), and 6 months postoperative (T2). Vaginal sonography was performed preoperatively and once again at 6 months postoperatively. Results: The median (Q1–Q3) LDH values dropped significantly postoperatively: 239 (217–266) U/L at T0 versus 217 (190–255) U/L at T1, p < 0.001. The median (Q1–Q3) IGF-1 values also dropped: 140.4 (118.6–179.0) ng/mL versus 112.4 (99.5–143.0), p < 0.001. By contrast, the CA 125 values rose slightly but not significantly. At 6 months (n = 34), the LDH values were not significantly different from either the preoperative or the immediate postoperative values. This was observed both in patients with and without a recurrence of myoma. In contrast, the median (Q1–Q3) IGF-1 level at T2 was significantly elevated both in patients with sonographic evidence of new myomas (129.0 [116.0–163.1] ng/mL, p = 0.023) and in patients with sonographic proof of no new myomas (161.0 [130.2–198.5] ng/mL, p < 0.001). Conclusion: Both LDH and IGF-1 dropped significantly in the immediate postoperative days in women with myomas after uterus-preserving surgeries were performed. The postoperative concentration of IGF-1 was correlated with the evidence of new myomas and can be potentially used for further monitoring. Future studies should be able to confirm these results. This study concludes that myomas do influence LDH and IGF-1 and could possibly be suitable as biomarkers.

[1]  Zhiming Hao,et al.  IGF-1 and VEGF can be used as prognostic indicators for patients with uterine fibroids treated with uterine artery embolization. , 2016, Experimental and therapeutic medicine.

[2]  W. Catherino,et al.  Uterine fibroids , 2016, Nature Reviews Disease Primers.

[3]  J. Cunha-Filho,et al.  Serum Prolactin and CA-125 Levels as Biomarkers of Peritoneal Endometriosis , 2015, Gynecologic and Obstetric Investigation.

[4]  M. Muhcu,et al.  CA 125 and other tumor markers in uterine leiomyomas and their association with lesion characteristics. , 2014, International journal of clinical and experimental medicine.

[5]  B. Borah,et al.  The impact of uterine leiomyomas: a national survey of affected women. , 2013, American journal of obstetrics and gynecology.

[6]  M. Hill,et al.  Biomarkers in uterine leiomyoma. , 2013, Fertility and sterility.

[7]  B. De Moor,et al.  Evaluation of a panel of 28 biomarkers for the non-invasive diagnosis of endometriosis. , 2012, Human reproduction.

[8]  R. Christenson,et al.  Methodological and analytic considerations for blood biomarkers. , 2012, Progress in cardiovascular diseases.

[9]  D. Dunson,et al.  Uterine Leiomyomata in Relation to Insulin-like Growth Factor-I, Insulin, and Diabetes , 2009, Epidemiology.

[10]  M. Mizuguchi,et al.  Expression of insulin-like growth factors (IGFs) and IGF signaling: molecular complexity in uterine leiomyomas. , 2009, Fertility and sterility.

[11]  L. R. Medeiros,et al.  Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. , 2009, European journal of obstetrics, gynecology, and reproductive biology.

[12]  A. Giatromanolaki,et al.  Serum and Tissue LDH Levels in Patients with Breast/Gynaecological Cancer and Benign Diseases , 2008, Gynecologic and Obstetric Investigation.

[13]  R. E. Blake,et al.  Leiomyomata uteri: hormonal and molecular determinants of growth. , 2007, Journal of the National Medical Association.

[14]  W. Parker.  Etiology, symptomatology, and diagnosis of uterine myomas. , 2007, Fertility and sterility.

[15]  T. Gungor,et al.  Serum leptin levels in women with uterine leiomyomas. , 2007, Taiwanese journal of obstetrics & gynecology.

[16]  K. Tsao,et al.  Elevation of CA 19‐9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis , 2007, Journal of clinical laboratory analysis.

[17]  P. Vercellini,et al.  Uterine leiomyoma and menstrual cycle characteristics in a population-based cohort study. , 2004, Human reproduction.

[18]  E. Bańkowski,et al.  An accumulation of insulin-like growth factor I (IGF-I) in human myometrium and uterine leiomyomas in various stages of tumour growth. , 2004, European cytokine network.

[19]  K. Sugimura,et al.  Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus , 2001, International Journal of Gynecologic Cancer.

[20]  P. Kamath,et al.  Cancer antigen 125 in patients with chronic liver disease. , 2002, Mayo Clinic proceedings.

[21]  D. Leroith,et al.  Dysregulation of IGF-I signaling in uterine leiomyoma. , 2002, The Journal of endocrinology.

[22]  J. Haseman,et al.  Immunohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium. , 2000, Environmental health perspectives.

[23]  F. Khan-dawood,et al.  Plasma insulin-like growth factor-I, CA-125, estrogen, and progesterone in women with leiomyomas. , 1994, Fertility and sterility.

[24]  R. Bast,et al.  The CA 125 tumour-associated antigen: a review of the literature. , 1989, Human reproduction.

[25]  K. Takahashi,et al.  Clinical usefulness of determination of CA 125 levels in the serum and menstrual blood. , 1988, Gynecologic and obstetric investigation.